The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Headline
The World Health Organization today declared the Ebola virus disease outbreak in the Democratic Republic of the Congo a public health emergency of…
Headline
The Centers for Medicare…
Headline
CMS anticipates releasing later this summer the feedback it received on potential methodology changes to the overall hospital quality star ratings, the agency…
Headline
The Health Resources and Services Administration yesterday recognized 10 states whose critical access hospitals had the highest quality reporting rates and…
Headline
Two investigational Ebola treatments being used in the ongoing outbreak in the Democratic Republic of the Congo are effective in laboratory studies.
Headline
HHS will bring together key health care stakeholders and government leaders to discuss how current quality programs can deliver better outcomes for patients.